Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827840 | 0.80 | ERN1 (0.42) | CYP11B2CYP11B1CYP19A1CYP17A1ERN1 | |
| SCHEMBL5828259 | 0.76 | CYP2A6 (0.31) | — | |
| SCHEMBL14077378 | 0.67 | TRIM24 (0.49) | CYP11B2CYP11B1ERN1NPC1PGR | |
| SCHEMBL16381826 | 0.66 | ESR1 (0.52) | NPC1PGR | |
| SCHEMBL14077377 | 0.66 | ESR1 (0.52) | NPC1PGR | |
| SCHEMBL5828240 | 0.66 | ALDH1A1 (0.40) | CYP19A1ERN1CYP1A2 | |
| Bicarbonate SCHEMBL8750617 | 0.66 | TRIM24 (0.56) | ERN1 | |
| SCHEMBL26260198 | 0.65 | CYP11B2 (0.88) | CYP11B2CYP11B1CYP19A1CYP17A1ERN1 | |
| SCHEMBL19737563 | 0.64 | TTK (0.49) | CYP11B2CYP11B1CYP19A1CYP17A1ERN1 | |
| SCHEMBL958907 | 0.64 | ERN1 (0.57) | CYP11B2CYP11B1CYP19A1CYP17A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | CYP11B2 52/4885CYP11B1 31/4885CYP19A1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.